Previous close | 3.8000 |
Open | 3.8000 |
Bid | 14.2000 |
Ask | 18.1000 |
Strike | 132.00 |
Expiry date | 2024-06-07 |
Day's range | 3.8000 - 3.8000 |
Contract range | N/A |
Volume | |
Open interest | 71 |
DexCom (DXCM) announces the direct connectivity of its G7 CGM system to Apple Watch for users in the United States, the UK, and Ireland.
SAN DIEGO, June 05, 2024--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects directly to Apple Watch* in the United States. Dexcom G7 is the first and only CGM available with Direct to Apple Watch, offering users the freedom and convenience of real-time glucose readings on their wrist even when their iPhone isn’t with them.†
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.